Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-06, Stock:LLY, The news for the past five days is as follows:
2018-03-29: NEWS1: What’s behind Omeros’s Cash Flow.NEWS2: What’s behind Omeros’s Cash Flow.NEWS3: Analysts’ Ratings for Omeros and Peers in March 2018.NEWS4: Analysts’ Ratings for Omeros and Peers in March 2018.NEWS5: Eli Lilly’s Segment-by-Segment Performance in 4Q17.NEWS6: Eli Lilly’s Segment-by-Segment Performance in 4Q17.NEWS7: Eli Lilly’s Revenue in 4Q17.NEWS8: Eli Lilly’s Revenue in 4Q17.NEWS9: Eli Lilly and Company’s Valuation in March 2018.NEWS10: Eli Lilly and Company’s Valuation in March 2018.
2018-04-02: NEWS1: Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year.NEWS2: Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year.NEWS3: A Look at the 4Q17 Performance of Eli Lilly’s Elanco.NEWS4: A Look at the 4Q17 Performance of Eli Lilly’s Elanco.NEWS5: How Eli Lilly’s Neuroscience Products Performed in 4Q17.NEWS6: How Eli Lilly’s Neuroscience Products Performed in 4Q17.NEWS7: Understanding Athenex’s Research Platforms.NEWS8: Analysts’ Ratings for Athenex and Its Peers in March.NEWS9: Understanding Athenex’s Research Platforms.NEWS10: Analysts’ Ratings for Athenex and Its Peers in March.NEWS11: How Eli Lilly’s Cardiovascular Products Performed in 4Q17.
2018-04-03: NEWS1: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS2: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS3: How United Therapeutics’ Adcirca and Orenitram Performed in 2017.NEWS4: How United Therapeutics’ Adcirca and Orenitram Performed in 2017.NEWS5: Analysts’ Recommendations for Eli Lilly in March 2018.NEWS6: Analysts’ Recommendations for Eli Lilly in March 2018.NEWS7: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS8: Will These Drugs Reach Blockbuster Status?.NEWS9: Will These Drugs Reach Blockbuster Status?.NEWS10: BRIEF-Tasly Pharma's Unit Signs Licensing Agreement On Diabetes Medicine With Eli Lilly.
2018-04-04: NEWS1: Lilly Confirms Date and Conference Call for First-Quarter 2018 Financial Results Announcement.NEWS2: Why Exelixis Will Triumph In Liver Cancer Battle With Eli Lilly.NEWS3: Health Care Sector Update for 04/04/2018: SNN,AMRN,GSK,LLY.NEWS4: Health Care Sector Update for 04/04/2018: SNN,AMRN,GSK,LLY.NEWS5: Health Care Sector Update for 04/04/2018: AMRN,GSK,LLY.NEWS6: Health Care Sector Update for 04/04/2018: AMRN,GSK,LLY.NEWS7: Running behind Gilead, Peninsula drug startup plots China dash for NASH.NEWS8: Lilly's Cyramza succeeds in late-stage liver cancer trial.NEWS9: Health Care Sector Update for 04/04/2018: LLY, AMRN, GSK.NEWS10: Health Care Sector Update for 04/04/2018: LLY, AMRN, GSK.NEWS11: Eli Lilly enters collaboration deal with Siligon for diabetes treatment, to take charge for in-process research.NEWS12: Eli Lilly enters collaboration deal with Siligon for diabetes treatment, to take charge for in-process research.NEWS13: Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes.NEWS14: Fast-growing Cambridge biotech Sigilon inks $63M diabetes deal with Eli Lilly.NEWS15: Eli Lilly reports positive results in late-stage trial of liver cancer treatment.NEWS16: Eli Lilly reports positive results in late-stage trial of liver cancer treatment.NEWS17: Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint.NEWS18: Eli Lilly, Sigilon Announce Global Collaboration - Quick Facts.NEWS19: Eli Lilly, Sigilon Announce Global Collaboration - Quick Facts.NEWS20: Eli Lilly: CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint - Quick Facts.NEWS21: Eli Lilly: CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint - Quick Facts.
2018-04-05: NEWS1: Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study.NEWS2: Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study.NEWS3: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS4: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS5: Lilly&apos;s Cyramza Shows Survival Benefit in Liver Cancer Study.NEWS6: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS7: CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct..NEWS8: CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct..

Answer: Decrease